For Roche and Genentech, What’s An Agreement Between Friends?
This article was originally published in The Pink Sheet Daily
Executive Summary
Ten-year-old affiliation agreement complicates Roche’s next moves and may give Genentech some leverage, as next steps include what one analyst calls “the nuclear option”
You may also be interested in...
Where Does Avastin Go From Here: Moving Beyond The C-08 Failure
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
Where Does Avastin Go From Here: Moving Beyond The C-08 Failure
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid
New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.